Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement

Ludger Klimek, Marek Jutel, Cezmi Akdis, Jean Bousquet, Mübeccel Akdis, Claus Bachert, Ioana Agache, Ignacio Ansotegui, Anna Bedbrook, Sinthia Bosnic-Anticevich, G. Walter Canonica, Tomas Chivato, Alvaro A. Cruz, Wienczyslawa Czarlewski, Stefano Del Giacco, Hui Du, Joao A. Fonseca, Yadong Gao, Tari Haahtela, Karin Hoffmann-SommergruberJuan-Carlos Ivancevich, Nikolai Khaltaev, Edward F. Knol, Piotr Kuna, Desiree Larenas-Linnemann, Erik Melen, Joaquim Mullol, Robert Naclerio, Ken Ohta, Yoshitaka Okamoto, Liam O’Mahony, Gabrielle L. Onorato, Nikos G. Papadopoulos, Ruby Pawankar, Oliver Pfaar, Boleslaw Samolinski, Jurgen Schwarze, Sanna Toppila-Salmi, Mohamed H. Shamji, Maria Teresa Ventura, Arunas Valiulis, Arzu Yorgancioglu, Paolo Matricardi, Torsten Zuberbier, the ARIA-MASK Study Group

Research output: Contribution to journalArticlepeer-review

94 Citations (Scopus)

Abstract

The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
Original languageEnglish
Pages (from-to)1546-1554
Number of pages9
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume75
Issue number7
DOIs
Publication statusPublished - Jul 2020
Externally publishedYes

Keywords

  • allergy treatment
  • immunotherapy clinical
  • immunotherapy vaccines and mechanisms

Fingerprint

Dive into the research topics of 'Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement'. Together they form a unique fingerprint.

Cite this